Eiger BioPharmaceuticals, Inc.
EIGR
株式のランク
#36458
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
株価
$1.73
最終同期: 2025-06-17
時価総額
$2.55M
変化（1日）
-0.29%
変化（1年）
-79.71%
国
US
取引 Eiger BioPharmaceuticals, Inc. (EIGR)
カテゴリー
Healthcare
Eiger BioPharmaceuticals, Inc.（EIGR）の利益
Dec 2023 時点の利益 TTM: $-74.96M
Eiger BioPharmaceuticals, Inc. の最新の財務報告によると、同社の現在の利益は $-74.96M です。2022 年には $-96.75M の利益を上げ、これは 2021 年の利益 $-33.85M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Eiger BioPharmaceuticals, Inc. の利益の推移（2016 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-74.96M | 0.00% |
| 2023 | $-74.96M | -22.53% |
| 2022 | $-96.75M | 185.80% |
| 2021 | $-33.85M | -47.96% |
| 2020 | $-65.05M | -7.40% |
| 2019 | $-70.25M | 34.09% |
| 2018 | $-52.39M | 23.42% |
| 2017 | $-42.45M | -9.85% |
| 2016 | $-47.09M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -7,137.23% |
US
|
|
| $-3.09B | 4,018.36% |
US
|
|
| $-4.02B | 5,258.00% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,702.36% |
NL
|
